B·R·A·H·M·S™ PlGF plus KRYPTOR™

B·R·A·H·M·S provides a complete portfolio of biomarkers for the management of pre-eclampsia throughout the pregnancy. B·R·A·H·M·S PlGF plus KRYPTOR is indicated as an aid for the early identification of women at risk of early onset pre-eclampsia in the first trimester, and with B·R·A·H·M·S sFlt-1 KRYPTOR, as aid for early prediction, diagnosis, and prognosis of pre-clampsia from week 20 and an identification of women at risk of developing term pre-eclampsia at week 36. The B·R·A·H·M·S PlGF plus KRYPTOR test is also indicated as an aid to be used in conjunction with the clinical evaluation for non-invasive risk assessment of fetal trisomy 21 in first trimester in pregnant women. Get confidence in your results with the high precision of B·R·A·H·M·S PlGF plus KRYPTOR and get results in less than 30 minutes.

• Incubation time of only 29 minutes for a short turnaround time
• Allows measurement in serum and plasma (EDTA)
• Large capacity with 75 tests
• Kit stable up to 29 days after opening onboard the instrument
• Easy workflow with only 1 calibrator and one calibration every 2 weeks
• Fits your throughput need with B·R·A·H·M·S KRYPTOR compact PLUS or B·R·A·H·M·S KRYPTOR GOLD
• Easy to use with sFlt-1/PlGF ratio calculated by the instrument
• Allows risk calculation in first trimester with B·R·A·H·M·S Fast screen pre I plus

• Intended Use for US Only: The B·R·A·H·M·S™ sFlt-1/ PlGF KRYPTOR™ Test System is comprised of the B·R·A·H·M·S PlGF plus KRYPTOR assay and the B·R·A·H·M·S sFlt-1 KRYPTOR assay. The B·R·A·H·M·S PlGF plus KRYPTOR is to be used in conjunction with the B·R·A·H·M·S sFlt-1 KRYPTOR along with other laboratory tests and clinical assessments to aid in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by American College of Obstetricians and Gynecologists guidelines) within 2 weeks of presentation.